Experimental Therapeutics (ET)

实验治疗学 摘要 亨斯迈癌症研究所（HCI）的实验治疗（ET）项目是连接和 协调基础科学的发现与转化研究和临床试验，以提高 癌症患者的诊断、疾病管理和治疗结果。这个广泛的计划 协调来自众多不同部门的教师进行有关机制的研究 正常和异常细胞生物化学、生理学、药理学以及分子和细胞生物学， 医生科学家和临床研究人员。总体目标是通过以下方式改善患者结局： 识别和验证新的治疗方法，促进转化研究，以适应实验室 观察新的干预措施，并进行临床研究，以评估新的干预措施的有效性。 人类的治疗方法。 ET计划的目的包括发现和翻译的HCI研究到临床实践，通过 开发新的治疗干预措施，原始药物启动的试验（IIT），行业试验（包括 首次人体试验），以及与国家癌症试验网络（NCTN）合作的试验，所有这些试验都有特殊的 重点是HCI的集水区--犹他州中特别相关的癌症。具体目标 是：1）基于HCI科学的发现开发新的癌症疗法，2）开发创新的 治疗干预措施，并进行转化和临床研究，特别侧重于癌症 与HCI的集水区有关。 ET计划的59名成员属于犹他州三所学校/学院的15个部门。 截至2018年底，同行评审的癌症相关资金为490万美元，其中260万美元（53%）来自 美国国家癌症研究所.项目成员还拥有980万美元的行业资金。在前一个周期中， ET成员发表了970篇同行评审的癌症研究论文。其中，20%来自内部。 方案合作，而23%是方案间合作。此外，该方案 2018年共有288项介入治疗试验，累计676名患者。 ET计划有助于HCI改善癌症预后的总体使命的成功 患者特别是，我们：1）翻译深刻的基本机制理解和开创性的临床前 将转化研究转化为原始临床试验，以及2）收集并进行来自 患者进行临床试验，以提高我们对疾病机制和治疗敏感性的理解， 人类的抵抗。展望未来，ET计划将努力使研究全循环，以推动 发现、临床前转化、临床试验和床旁到实验台分析的良性循环。

EXPERIMENTAL THERAPEUTICS PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program at Huntsman Cancer Institute (HCI) is the hub that connects and coordinates discoveries made in the basic sciences with translational research and clinical trials to improve diagnostics, disease management, and treatment outcomes for cancer patients. This broad-reaching program coordinates faculty from numerous and diverse departments conducting research on mechanisms underlying normal and abnormal cellular biochemistry, physiology, pharmacology, and molecular and cell biology with physician-scientists and clinical researchers. The overarching goal is to improve patient outcomes by identifying and validating novel treatment approaches, fostering translational research to adapt laboratory observations into novel interventions, and conducting clinical research to assess the effectiveness of new treatment approaches in humans. ET Program Aims encompass discovery and translation of HCI research into clinical practice through development of novel treatment interventions, original investigator-initiated trials (IITs), industry trials (including first-in-human trials), and trials in cooperation with the National Cancer Trials Network (NCTN), all with special emphasis on cancers of particular relevance in HCI’s catchment area—the State of Utah. The Specific Aims are: 1) to develop new cancer therapies based on discoveries from HCI science, and 2) to develop innovative treatment interventions and conduct translational and clinical research, with special emphasis on cancers relevant to HCI’s catchment area. The ET Program’s 59 members belong to 15 departments within three University of Utah schools/colleges. Peer-reviewed cancer-related funding was $4.9M at the end of 2018, with $2.6M (53%) of that from the National Cancer Institute. Program members also hold $9.8M in industry funding. During the previous cycle, ET members published 970 peer-reviewed cancer research papers. Of these, 20% resulted from intra- programmatic collaborations, while 23% represent inter-programmatic collaborations. Further, the Program houses 288 interventional treatment trials that accrued 676 patients in 2018. The ET Program is instrumental to the success of HCI’s overall mission to improve the outcomes of cancer patients. In particular, we: 1) translate deep basic mechanistic understandings and pioneering preclinical translational research into original clinical trials, and 2) collect and conduct iterative analysis of specimens from patients on clinical trials to improve our understanding of disease mechanisms and therapeutic sensitivity or resistance in human beings. Going forward, the ET Program will strive to bring research full circle to fuel a virtuous cycle of discovery, preclinical translation, clinical testing, and bedside-to-bench analyses.